Skip to content
value.today

ZS Pharma, Inc.

🇺🇸 Lafayette, Indiana, USAPharmaceuticalsFounded 2008
Total raised
$59 M
4 rounds on record
Latest round
$25 M
Feb 2014
First round on record
Feb 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of ZS Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2014$25 MNo. 4$10 to $50 million

ZS Pharma, Inc.: Raise no. 4, Feb 2014

Investors in this round

12 investors had bought by the notice of Mar 11, 2014: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for ZS Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alvaro F. Guillem · Executive Officer, Director
  • Cynthia B. Smith · Executive Officer
  • Donald Jeffrey Keyser · Executive Officer, Director
  • Henrick Sandvad Rasmussen · Executive Officer
  • Robert B. Alexander · Executive Officer, Director
  • Todd B. Creech · Executive Officer
  • Guy B. Nohra · Director
  • John B. McKearn · Director
  • Marc B. Ostro · Director
  • Robert B. Truitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by D. Jeffrey Keyser, Chief Operating Officer and Secretary. Source: SEC Form D, newest notice filed Mar 11, 2014. Read the notice at the SEC.

equitySEC
Oct 2012$28 MNo. 3$10 to $50 million

ZS Pharma, Inc.: Raise no. 3, Oct 2012

Investors in this round

6 investors had bought by the notice of Oct 23, 2012: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for ZS Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $46 M offered; $18 M still to sell
Smallest investment taken
$256,318
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,656,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alvaro F. Guillem · Executive Officer, Director
  • Donald Jeffrey Keyser · Executive Officer, Director
  • Henrick Sandvad Rasmussen · Executive Officer
  • Nels P. Bergmark · Executive Officer
  • Stephen R. Ash · Executive Officer
  • John B. McKearn · Director
  • Marc B. Ostro · Director
  • Miles B. Davis · Director
  • Robert B. Alexander · Director
  • Robert B. Truitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Salem Partners LLC (CRD 43363) · Los Angeles, CaliforniaSold in CA, MO, PA

Signed by Al Guillem, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 23, 2012. Read the notice at the SEC.

equitySEC
Nov 2011$5 MNo. 2$2 to $10 million

ZS Pharma, Inc.: Raise no. 2, Nov 2011

Investors in this round

12 investors had bought by the notice of Jul 10, 2012: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for ZS Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$20,000
What was sold
equity, debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$258,300
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alvaro F. Guillem · Executive Officer, Director
  • Donald Jeffrey Keyser · Executive Officer, Director
  • Henrick Sandvad Rasmussen · Executive Officer
  • Nels P. Bergmark · Executive Officer
  • Stephen R. Ash · Executive Officer
  • Marc B. Ostro · Director
  • Miles B. Davis · Director
  • Robert B. Truitt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Salem Partners LLC (CRD 43363) · Los Angeles, CaliforniaSold in CA, CO, FL, IN, MA, PA, TX

Signed by Al Guillem, President and Chief Executive Officer. Source: SEC Form D and 2 amendments, newest notice filed Jul 10, 2012. Read the notice at the SEC.

equity, debt, optionsSEC
Feb 2009$1 MNo. 1Under $2 million

ZS Pharma, Inc.: Raise no. 1, Feb 2009

Investors in this round

30 investors had bought by the notice of Dec 13, 2010: 30 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 11 investors are named for ZS Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $3 M offered; $2 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alvaro F Guillem · Executive Officer, Director · President and CEO
  • Donald Jeffery Keyser · Executive Officer, Director · Chief Operating Officer
  • Joy B Barton · Executive Officer · Chief Business Officer
  • Nels R Bergmark · Executive Officer · Treasurer
  • Robert B Truitt · Executive Officer, Director · Chairman of the Board of Directors
  • Stephen R Ash · Executive Officer · Chief Medical Officer
  • Tim B Opler · Executive Officer, Director · Vice President, Strategy
  • William B Kushner · Executive Officer · Vice President, Legal Affairs

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Alvaro Guillem, President and CEO. Source: SEC Form D, newest notice filed Dec 13, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • ZS Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2014).

    SEC Form D · Mar 2014

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2014

That is all the official record says: ZS Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

11 named in official filings. Open an investor to see everything it has backed.

Investors in ZS Pharma, Inc.
InvestorKindAmountRoundRoleSource
3x5 Special Opportunity Fund, L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alta Partners Management VIII, LLCFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alta Partners VIII, L.P.Fund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Alvaro GuillemPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2014)SEC Form 3
Devon Park Associates, LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Devon Park Associates, L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Devon Park Bioventures LPVenture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
D. Jeffrey KeyserPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2014)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Rivervest Venture Fund II L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3
RiverVest Venture Fund II (Ohio), L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 30 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by ZS Pharma, Inc.
NameRoleNamed in
Alvaro F. GuillemExecutive officerMar 2014
Cynthia B. SmithExecutive officerMar 2014
Donald Jeffrey KeyserExecutive officerMar 2014
Henrick Sandvad RasmussenExecutive officerMar 2014
Robert B. AlexanderExecutive officerMar 2014
Todd B. CreechExecutive officerMar 2014
Nels P. BergmarkExecutive officerOct 2012
Stephen R. AshExecutive officerOct 2012
Alvaro F GuillemPresident and CEODec 2010
Donald Jeffery KeyserChief Operating OfficerDec 2010
Joy B BartonChief Business OfficerDec 2010
Nels R BergmarkTreasurerDec 2010
Robert B TruittChairman of the Board of DirectorsDec 2010
Stephen R AshChief Medical OfficerDec 2010
Tim B OplerVice President, StrategyDec 2010
William B KushnerVice President, Legal AffairsDec 2010
Alvaro F. GuillemDirectorMar 2014
Donald Jeffrey KeyserDirectorMar 2014
Guy B. NohraDirectorMar 2014
John B. McKearnDirectorMar 2014
Marc B. OstroDirectorMar 2014
Robert B. AlexanderDirectorMar 2014
Robert B. TruittDirectorMar 2014
Miles B. DavisDirectorOct 2012
Alvaro F GuillemPresident and CEODec 2010
Donald Jeffery KeyserChief Operating OfficerDec 2010
Robert B TruittChairman of the Board of DirectorsDec 2010
Tim B OplerVice President, StrategyDec 2010